| Nov 21 |
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
|
| Nov 12 |
Replimune Group GAAP EPS of -$0.68 beats by $0.09
|
| Nov 12 |
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
|
| Nov 9 |
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
|
| Nov 8 |
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 30 |
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
|
| Oct 9 |
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 8 |
Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
|
| Oct 2 |
Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate
|
| Sep 15 |
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
|
